ArticleBMC cancer2021
Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis.
Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Understanding the value of brain donation for research to donors, next-of-kin and clinicians: A systematic review.PloS one · 2023Pooled it
- Prognostic nomogram for glioblastoma (GBM) patients presenting with distant extension: a seer-based study.Journal of cancer research and clinical oncology · 2023Trial
- Single-cell profiling identifies a pro-tumoral VCAN positive macrophage subset and defines a prognostic signature in glioblastoma.Discover oncology · 2026Article
- MRI semantic features as prognostic indicators and biological mechanism insights in glioblastoma multiforme.Neurosurgical review · 2026Article
- Graphene quantum dot-integrated nanocomposites: a promising avenue for glioblastoma treatment.Medical oncology (Northwood, London, England) · 2025Review
- Integrated Workflow for Drug Repurposing in Glioblastoma: Computational Prediction and Preclinical Validation of Therapeutic Candidates.Brain sciences · 2025Article
- Predicting Treatment Outcomes in Glioblastoma: A Risk Score Model for TMZ Resistance and Immune Checkpoint Inhibition.Biology · 2025Article
- Advancing brain tumor therapy: unveiling the potential of PROTACs for targeted protein degradation.Cytotechnology · 2025Review
- Overcoming immune evasion with innovative multi-target approaches for glioblastoma.Frontiers in immunology · 2025Review
- Risk Factors and Predictive Nomogram for Survival in Elderly Patients with Brain Glioma.Current medical science · 2024Article
- The Effect of Therapy Regimen on Antitumor Efficacy of the Nanosomal Doxorubicin against Rat Glioblastoma 101.8.Bulletin of experimental biology and medicine · 2024Article
- Comprehensive Transcriptomic Profiling of Diverse Brain Tumor Types Uncovers Complex Structures of the Brain Tumor Microenvironment.Biomedicines · 2024Article
- Survival prediction of glioblastoma patients using modern deep learning and machine learning techniques.Scientific reports · 2024Article
- A two-pronged approach against glioblastoma: drug repurposing and nanoformulation design for in situ-controlled release.Drug delivery and translational research · 2023Article
- S100A6 is a potential diagnostic and prognostic biomarker for human glioma.Oncology letters · 2023Article
- Clinical features and outcomes of pediatric intracranial gliomas: results from single center's 226 cases and corroborated with SEER database.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2023Article
- Valproic acid as a radio-sensitizer in glioma: A systematic review and meta-analysis.Neuro-oncology practice · 2023Article
- An update on neurobiological mechanisms involved in the development of chemotherapy-induced cognitive impairment (CICI).Toxicology reports · 2023Review
- Double Immunohistochemical Staining on Formalin-Fixed Paraffin-Embedded Tissue Samples to Study Vascular Co-option.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Glioblastoma multiforme: Diagnosis, treatment, and invasion.Journal of biomedical research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma (GBM) is a highly malignant brain tumor with poor survival and prognosis. Randomized trials have demonstrated that chemotherapy improves survival in patients with GBM. This study aims to examine the clinical characteristics that are potentially associated with the efficacy of chemotherapy and the risk factors of GBM.
methodsA total of 25,698 patients diagnosed with GBM were identified between 2004 and 2015 from the Surveillance, Epidemiology, and End Results (SEER). The clinical and demographic variables between groups were examined by Student's t-test and Pearson's chi-square test. GBM-specific survival (GBMSS) and overall survival (OS) were evaluated using the Kaplan-Meier method with the log-rank test. Univariable and multivariable analyses were also performed using the Cox proportional hazards model to identify statistically significant prognostic factors.
resultsPatients who received chemotherapy had better overall survival (median OS 13 vs. Three months, HR = 1.9224, 95%CI 1.8571-1.9900, p < 0.0001) and better GBMSS (median GBMSS of 12 vs. Three months, HR = 1.9379, 95%CI 1.8632-2.0156, p < 0.0001), compared to patients who did not. Further subgroup analysis revealed that among patients who underwent chemotherapy, those who were younger, with a supratentorial tumor, received surgery, or radiotherapy had both improved OS and GBMSS. Age, race, tumor location, tumor size, and treatments were identified as independent prognostic factors by multivariable analyses for patients with glioblastoma.
conclusionPatients with GBM who were younger (< 65 years), underwent surgery, or radiotherapy can benefit more from chemotherapeutic regimens. Age, race, tumor size, tumor location, surgery, radiotherapy, and chemotherapy were factors associated with the prognosis of patients with GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.